Prof. Xiaohua Wu (吴小华)
MD, PhD — Director of Gynecologic Oncology, Fudan University Shanghai Cancer Center
Clinical Trial Leadership: Prof. Wu is the principal investigator of the GC203 clinical trial evaluating TIL therapy for recurrent ovarian cancer. GC203 is exploring the potential of TIL therapy for gynecologic malignancies, an area with significant unmet medical need.
Clinical Trial Leadership
Prof. Xiaohua Wu leads the GC203 clinical trial investigating TIL therapy for patients with recurrent ovarian cancer. This study represents one of the first clinical applications of TIL therapy in gynecologic malignancies and builds on Prof. Wu's extensive experience in ovarian cancer surgery and clinical research.
Professional Affiliations
- Director, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center
- Chairperson, Chinese Gynecologic Cancer Society (CGCS)
- Chairman, Gynecologic Oncology Committee, Chinese Anti-Cancer Association (CACA)
- Editorial Board Member, Gynecologic Oncology (International Journal)
- Leading expert in cervical cancer surgery — developed the "Fudan Criteria" for fertility-sparing surgery
Career & Milestones
GC203 TIL Therapy for Ovarian Cancer
Leading the first TIL therapy clinical trial in China specifically targeting gynecologic malignancies. The study evaluates the safety and preliminary efficacy of GC101-based TIL therapy in patients with recurrent ovarian cancer who have progressed after platinum-based chemotherapy.
Role at Fudan University Shanghai Cancer Center
As Director of Gynecologic Oncology at one of China's leading cancer centers, Prof. Wu oversees the largest gynecologic oncology service in the region, managing a high-volume surgical and clinical practice spanning ovarian, cervical, and endometrial cancers.
Research Focus
Prof. Wu's research focuses on improving outcomes for patients with gynecologic malignancies through innovative surgical techniques and novel therapeutic strategies. His group has been instrumental in establishing clinical pathways for cell therapy in ovarian cancer, a disease where effective treatment options after platinum resistance remain extremely limited.
External Resources
Frequently Asked Questions About Prof. Xiaohua Wu
Who is Prof. Xiaohua Wu?
Prof. Xiaohua Wu (吴小华) is Professor and Director of Gynecologic Oncology at Fudan University Shanghai Cancer Center and President of the Chinese Gynecologic Cancer Society (CGCS). He is a world-renowned expert in ovarian cancer surgery and clinical research.
What is Prof. Wu's role in TIL therapy research?
Prof. Wu is Principal Investigator of the GC203 gene-edited TIL therapy trial for recurrent ovarian cancer at Fudan University Shanghai Cancer Center. This is one of the first TIL therapy studies in China specifically targeting gynecologic malignancies.
What are Prof. Wu's professional titles?
Prof. Wu serves as President of the Chinese Gynecologic Cancer Society (CGCS), Chairman of the Gynecologic Oncology Committee of CACA, and Director of Gynecologic Oncology at Fudan University Shanghai Cancer Center. He also serves on the editorial board of Gynecologic Oncology.
How can I consult with Prof. Wu about ovarian cancer TIL therapy?
Patients interested in the GC203 TIL therapy trial for ovarian cancer can contact CancerPath at clinicaltrials@juncell.com for a free eligibility assessment. Prof. Wu leads the trial at Fudan University Shanghai Cancer Center.
Explore TIL Therapy for Ovarian Cancer
Learn more about GC203 and other TIL therapy options for gynecologic malignancies.
Contact us →